Clinical Trials Browser

Urinary Bladder Neoplasms, Bone Neoplasms, Brain Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Glioblastoma, Hodgkin Disease, Kidney Neoplasms, Leukemia, Lung Neoplasms, Lymphoma, Lymphoma, Non-Hodgkin, Melanoma, Multiple Myeloma, Myelodysplastic Syndromes, Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Sarcoma, Osteosarcoma, Skin Neoplasms, Testicular Neoplasms, Thyroid Neoplasms, Leukemia, Myeloid, Acute, Hematologic Neoplasms, Small Cell Lung Carcinoma

NCT04185649 2019-12-04

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

Phase 3 Unknown

410 enrolled

Breast

HER2-positive Advanced Breast Cancer

NCT01479244 2017-02-27

PRESENT

Phase 3 Completed

758 enrolled

Breast

Breast Neoplasms

NCT02154139 2016-02-17

Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"

Completed

651 enrolled 12 charts

Breast

Breast Neoplasms

NCT00918281 2014-06-09

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

Phase 2 Completed

70 enrolled 9 charts

BreastGenitourinaryHead & NeckSarcomaThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Head and Neck Neoplasms, Lung Neoplasms, Sarcoma

NCT00041808 2005-06-24

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver

Phase 1/2 Completed

20 enrolled

BreastDermatologicGastrointestinalSarcomaThoracic

Breast Neoplasms, Esophageal Neoplasms, Gastrointestinal Neoplasms, Liver Neoplasms, Lung Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma, Gastrointestinal Stromal Tumors

Clinical Trials

Bioequivalence Study of Paclitaxel for Injection (Albumin Bound) in Subjects With Breast Cancer

A Study of MR001 in Patients With Locally Recurrent or Metastatic Advanced Triple-Negative Breast Cancer (TNBC)

A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer

A Trial of SHR-A1811 Compared to Other Antitumor Therapies as Neoadjuvant Treatments in Early-stage or Locally Advanced HER2-positive Breast Cancer

neoMono

A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer

Study to Evaluate Safety and Dosimetry of [18F]GEH121224 in Patients With Locally Advanced or Metastatic Breast Cancer

Safety, Efficacy and Pharmacokinetic Behavior of Leuprolide Injectable Emulsion for Premenopausal Breast Cancer Subjects.

A Clinical Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

JSKN003 Versus Treatment Of Physician'S Choice For HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects

A Study of YL202 in Combination With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors

A Study of Neoadjuvant Treatment With TQB2102 for Injection for Human Epidermal Growth Factor Receptor 2 (HER2) Positive Breast Cancer

Clinical Trial of TQB2102 for Injection Versus Trastuzumab Emtansine for Injection in HER2-positive Advanced Breast Cancer

A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer

Sirolimus for Injection (Albumin-bound) in Combination With Endocrine Therapy for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Who Have Failed Standard Therapy

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

Sirolimus for Injection (Albumin-bound) Combined With Fulvestrant for HR+/HER2- Advanced/Metastatic Breast Cancer Patients Previously Treated With CDK4/6 Inhibitors

Pharmacodynamic Study Goserelin 3.6mg Injection Administered Subcutaneously in Premenopausal Patients with Breast Cancer

QUILT-3.013: Study of Ad5 [E1-, E2b-]-HER2/Neu Vaccine (ETBX-021) in Subjects With Unresectable Locally Advanced or Metastatic HER2-Expressing Breast Cancer

Efficacy and Safety of Paclitaxel Polymeric Micelles for Injection in the Treatment of Metastatic Breast Cancer

The Clinical Trial of TQB2102 for Injection Against Human Epidermal Growth Factor Receptor 2 Negative Breast Cancer

A Study of BEBT-209 in Combination With Chemotherapy for the Treatment of Advanced Triple-Negative Breast Cancer

A Study of Bi-Ligand-Drug Conjugate CBP-1019 in Patients With Advanced Solid Tumors

A Clinical Trial to Evaluate the Efficacy and Safety of TQB2102 for Injection Versus Investigator-Selected Chemotherapy in HER2 Low-Expressing Recurrent/Metastatic Breast Cancer

To Evaluate the Efficacy and Safety of Disitamab Vedotin Combined With Toripalimab Sequential Chemotherapy as Neoadjuvant Treatment in Patients With HR-positive, HER2-low Breast Cancer

A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

A Study of TQB2102 for Injection in Patients With Recurrent/Metastatic Breast Cancer

FS-1502 Versus T-DM1 for HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer

A Study of SHR-A1811 Combined With Capecitabine in Treatment of Unresectable or Metastatic Breast Cancer With Low HER2 Expression.

Efficacy and Safety of LY01005 in Patients With Breast Cancer Compared to ZOLADEX®

Clinical Study to Compare the Pharmacokinetics and Safety of Trastuzumab for Injection With Herceptin® in Healthy Male Volunteers

A Study to Evaluate the Efficacy and Safety in Patients With Advanced Breast Cancer Treated With SYHX2011 Compared to Paclitaxel for Injection (Albumin-bound)

A Pharmacokinetic Study Comparing EG1206A and Perjeta (Pertzumab) in Healthy Male Volunteers

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Paclitaxel for Injection (Albumin Bound) in Subjects With Triple Negative Breast Cancer (TNBC)

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

The Efficacy and Safety of BAT8001 Injection for the Treatment of HER2-positive Advanced Breast Cancer

PRESENT

Leuprorelin Acetate SR 11.25 mg for Injection Specified Drug-use Survey "Long-term Use Survey on Premenopausal Breast Cancer Patients (96 Weeks)"

Reproducibility of 18F Uptake by Solid Tumors Using PET Imaging Following Intravenous Administration of (18F) Injection

Magnetic-Targeted Doxorubicin in Treating Patients With Cancer Metastatic to the Liver